Search results
Results from the WOW.Com Content Network
OpenBiome is a nonprofit health research organization based in Massachusetts accelerating research on the human microbiome. They partner with leading researchers, clinicians and innovators to advance and ensure access to novel and affordable microbiome therapeutics.
About The Microbiome Therapeutics Innovation Group The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.
The Danish Council of Bioethics in its Patenting Human Genes and Stem Cells Report [6] noted that "In the members' view, it cannot be said with any reasonableness that a sequence or partial sequence of a gene ceases to be part of the human body merely because an identical copy of the sequence is isolated from or produced outside of the human ...
The rapid enrolment reflects patient interest and the significant need for innovative IBS therapies that target microbiome imbalances, and we look forward to reporting topline data early next year.” About EnteroBiotix . EnteroBiotix is a clinical-stage biotechnology company developing therapeutics to treat gastrointestinal and hepatic diseases.
Venn diagram showing pharmacomicrobiomics as a sub-field of genomics, microbiology, and pharmacology. Pharmacomicrobiomics, proposed by Prof. Marco Candela for the ERC-2009-StG project call (proposal n. 242860, titled "PharmacoMICROBIOMICS, study of the microbiome determinants of the different drug responses between individuals"), and publicly coined for the first time in 2010 by Rizkallah et ...
Design of engineered live bacterial therapeutics [1]. Bacterial therapy is the therapeutic use of bacteria to treat diseases.Bacterial therapeutics are living medicines, and may be wild type bacteria (often in the form of probiotics) or bacteria that have been genetically engineered to possess therapeutic properties that is injected into a patient.
In 2012, Berry founded Seres Therapeutics, which pioneered microbiome therapeutics. [6] The company raised over $130M as a private company, including a $65M investment from Nestle Health Sciences. [7] Seres publicly listed on the Nasdaq under the symbol MCRB in June 2015, raising $134M. [8]
Drug Price Competition and Patent Term Restoration Act; Long title: An Act to amend the Federal Food, Drug, and Cosmetic Act to revise the procedures for new drug applications, to amend title 35, United States Code, to authorize the extension of the patents for certain regulated products, and for other purposes.